Диссертация (1154767), страница 14
Текст из файла (страница 14)
– 9(6). – С.698-700.21.Эрлих, А.Д, Результаты шестимесячного наблюдения за больными сострыми коронарными синдромами в Российском регистре РЕКОРД / ЭрлихА.Д, Грацианский Н. А. от имени участников регистра РЕКОРД //Кардиология.— 2011.— 12.— C.11-16.9422.Abramson, J.D. Should people at low risk of cardiovascular disease take astatin? / Abramson J.D, Rosenberg H.G., Jewell N., Wright J.M. // BMJ. —2013.— 347.23.Akao, H. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low densitylipoprotein cholesterol lowering response to pravastatin, and heart disease riskreduction in the elderly / Akao H., Polisecki E., Kajinami K., et al //Atherosclerosis.
— 2012. —220(2). — C.456-62.24.Arai, K. The I4399M variant of apolipoprotein(a) is associated withincreased oxidized phospholipids on apolipoprotein B-100 particles / Arai K., LukeM.M., Koschinsky M.L., et al. // Atherosclerosis. — 2010. —209(2). —C. 498503.25.Arsenault, B.J. Impact of high-dose atorvastatin therapy and clinical riskfactors on incident aortic valve stenosis in patients with cardiovascular disease(from TNT, IDEAL, and SPARCL) / Arsenault B.J.,Boekholdt S. M.,Mora S.,DeMicco D.A.,Bao W.
at al // Am J Cardiol. — 2014. —113. — C.1378–1382.26.Baigent, C. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacyand safety of more intensive lowering of LDL cholesterol: a meta-analysis of datafrom 170,000 participants in 26 randomised trials/ Baigent C, Blackwell L,Emberson J, et al // Lancet. — 2010. — 376. — C.1670-81.27.Becquemont, L. Pharmacogenomics. Practical recommendations forpharmacogenomics‐based prescription / Becquemont L., Alfirevic A., Amstutz U.et al // ESF‐UB Conference on Pharmacogenetics and Pharmacogenomics. —2010. — 12(1). — C.113‐124.28.Berglund, L.
Evaluation and treatment of hypertriglyceridemia: anEndocrine Society clinical practice guideline / Berglund L., Brunzell J.D.,Goldberg A.C. et al // J Clin Endocrinol Metab. — 2012. — 97(9). — C.29692989.29.Betteridge, D.J. Effect of rosuvastatin on LDL-C and CRP levels in patientswith type 2 diabetes: results of ANDROMEDA study / Betteridge D.J, Gibson M.// Atheroscler Suppl. — 2004. — 5. — C.107-108.9530.Bjornsson, E.
Hepatotoxicity associated with statins: reports of idiosyncraticliver injury post-marketing / Bjornsson E., Jacobsen E.I., Kalaitzakis E.// JHepatol. — 2012. — 56. — C.374–80.31.Boekholdt, S.M. Very low levels of atherogenic lipoproteins and the risk forcardiovascular events: a meta-analysis of statin trials / Boekholdt S.M, HovinghG.K., Mora S. et al // J Am Coll Cardiol. — 2014. —64.— C.485–494.32.Boerwinkle, E. Apolipoprotein(a) gene accounts for greater than 90% of thevariation in plasma lipoprotein(a) concentrations / Boerwinkle, E., Leffert C.C.,Lin J., Lackner C., Chiesa G., Hobbs H.H.
// J Clin Invest. — 1992. — 90(1). —C.52-60.33.Cannon, C.P. Ezetimibe added to statin therapy after acute coronarysyndromes / Cannon, C.P., Blazing M.A., Giugliano R.P. et al // N Engl J Med.—2015. —372. — C.2387-97.34.Cantin, B. Is lipoprotein(a) an independent risk factor for ischemic heartdisease in men? The Quebec Cardiovascular Study / Cantin, B., Gagnon F.,Moorjani S., et al. // J Am Coll Cardiol. — 1998. — 31(3).
— C.519-525.35.Carr, D.F., O’Meara H, Jorgensen AL, et al. SLCO1B1 Genetic VariantAssociated With Statin-Induced Myopathy: A Proof-of-Concept Study Using theClinical Practice Research Datalink. Clin Pharmacol Ther. — 2013. — 94(6). —C.695-701.36.Catapano, A.L., De Backer G, Wiklund O, et al. ESC/EAS Guidelines forthe management of dyslipidaemias. Eur Heart J. — 2016. —37. — C. 2999–3058.37.Chackathayil , J. Antecedents, characterisation and validity of cardiovasculardisease biomarkers amongst south asians in the UK.
— 2013.— C.65.38.Chasman, D.I., Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, RidkerPM. Genetic Determinants of Statin-Induced Low-Density Lipoprotein CholesterolReduction: The Justification for the Use of Statins in Prevention: An InterventionTrial Evaluating Rosuvastatin (JUPITER) Trial / Chasman DI, Giulianini F,96MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. // Circ Cardiovasc Genet. —2012 — 5(2). — C.257-264.39.Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in theapolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and lowdose aspirin therapy.
Atherosclerosis. 2009;203(2):371-376.40.Chiang C.E, Ferrières J, Gotcheva NN, et al. Suboptimal Control of LipidLevels: Results from 29 Countries Participating in the Centralized Pan-RegionalSurveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). JAtheroscler Thromb. 2016;23(5):567-587.41.Cholesterol Treatment Trialists’ (CTT) Collaboration.
Efficacy and safety ofLDL-lowering therapy among men and women: meta-analysis of individual datafrom 174 000 participants in 27 randomised trials / Cholesterol TreatmentTrialists’ (CTT) Collaboration, Fulcher J., O’Connell R., et al. // Lancet.2015;385(9976):1397-1405.42.Cohen DE, Anania FA, Chalasani N, National Lipid Association StatinSafety Task Force Liver Expert Panel. An assessment of statin safety byhepatologists. Am J Cardiol 2006; 97: C.77–81.43.Collins, Rory et al. Interpretation of the evidence for the efficacy and safetyof statin therapy. The Lancet , Volume 388 , Issue 10059 , 2532 - 2561.44.Cui, F. Apolipoprotein C3 genetic polymorphisms are associated with lipidsand coronary artery disease in a Chinese population / Cui F., Li K., Li Y., ZhangX., An C.
// Lipids Health Dis. – 2014. -13.- C. 170.45.Davies MJ. The pathophysiology of acute coronary syndromes. Heart.2000;83(3):361-366.46.De Caterina R, Talmud PJ, Merlini PA, et al. Strong association of theAPOA5-1131T>C gene variant and early-onset acute myocardial infarction.Atherosclerosis. 2011;214(2):397-403. doi:10.1016/j.atherosclerosis.2010.11.011.47.Ding, Y.
Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome/ Ding Y., Zhu M.A., Wang Z.X.,Zhu J., Feng J.B., Li D.S. // J Biomed Biotechnol. - 2012.- 509420.9748.Durrington PN, Schofield JD, Siahmansur T, Soran H. Lipoprotein (a). CurrOpin Lipidol.
2014;25(4):289-296.49.Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G.Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardialinfarction: Korean national health system prospective cohort study. BMJ 2006;333: 22.50.Edelberg JM, Gonzalez-Gronow M, Pizzo S V. Lipoprotein(a) inhibition ofplasminogen activation by tissue-type plasminogen activator.
Thromb Res.1990;57(1):155-162.51.Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) Isoformsand the Risk of Vascular Disease. J Am Coll Cardiol. 2010;55(19):2160-2167.52.Everett B, Mora S, Glynn RJ, MacFadyen J, Ridker PM. Safety profile ofindividuals treated to very low low-density lipoprotein cholesterol levels (<30mg/dL) with rosuvastatin 20 mg daily. Amer J Cardiol 2014. -114(11).
- C.16821689.53.Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial ofatorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74:956–64.54.Fu Q, Li Y-P, Gao Y, et al. Lack of association between SLCO1B1polymorphism and the lipid-lowering effects of atorvastatin and simvastatin inChinese individuals. Eur J Clin Pharmacol. 2013;69(6):1269-1274.55.García-Otín A-L, Civeira F, Aristegui R, et al. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combinedhyperlipidemia treatment.
Eur J Clin Invest. 2002;32(6):421-428.56.Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH. Humanplasma lipoprotein [a]. Structural properties. J Biol Chem. 1983;258(7):4582-4589.57.Gavish D, Azrolan N, Breslow JL. Plasma Ip(a) concentration is inverselycorrelated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a)gene. J Clin Invest. 1989;84(6):2021-2027.9858.Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism insubjects with deficiency of apolipoproteins CIII and AI. Evidence thatapolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins bylipoprotein lipase in vivo. J Clin Invest. 1986;78(5):1287-1295.59.Gitt AK, Drexel H, Feely J, et al.
Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinicalpractice in Europe and Canada. Eur J Prev Cardiol 2012; 19: 221–30.60.Hopewell JC, Parish S, Offer A, et al. Impact of common genetic variationon response to simvastatin therapy among 18 705 participants in the HeartProtection Study. Eur Heart J 2013;34(13):982-92.61.Hopewell JC, Parish S, Offer A, et al.
Impact of common genetic variationon response to simvastatin therapy among 18 705 participants in the HeartProtection Study. Eur Heart J. 2013;34(13):982-992.62.Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular eventreduction and adverse events among subjects attaining low-density lipoproteincholesterol,50mg/dlwithrosuvastatin.The JUPITER trial (Justification for the Useof Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am CollCardiol 2011;57:1666–1675.63.Hu M, Mak VWL, Tomlinson B. Intronic variants in SLCO1B1 related tostatin-induced myopathy are associated with the low-density lipoproteincholesterol response to statins in Chinese patients with hyperlipidaemia.Pharmacogenet Genomics.
2012;22(11):803-806.64.Hubacek JA, Adamkova V, Prusikova M, et al. Impact of apolipoprotein A5variants on statin treatment efficacy. Pharmacogenomics 2009;10(6):945-50.65.Ishihara M, Kujiraoka T, Iwasaki T, et al. A sandwich enzyme-linkedimmunosorbent assay for human plasma apolipoprotein A-V concentration. J LipidRes. 2005;46(9):2015-2022.66.Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serumcholesterol levels and six-year mortality from stroke in 350 977 men screened forthe multiple risk factor intervention trial.
N Engl J Med 1989; 320: 904–10.9967.Jang Y, Paik JK, Hyun YJ, et al. The apolipoprotein A5 -1131T>C promoterpolymorphism in Koreans: Association with plasma APOA5 and serumtriglyceride concentrations, LDL particle size and coronary artery disease.
ClinChim Acta. 2009;402(1-2):83-87.68.Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronaryheart disease risk: a nested case-control study of the Helsinki Heart Studyparticipants. Atherosclerosis. 1991;89(1):59-67.69.Jensen MK, Rimm EB, Furtado JD, Sacks FM. Apolipoprotein C-III as aPotential Modulator of the Association Between HDL-Cholesterol and IncidentCoronary Heart Disease. J Am Heart Assoc. 2012;1(2).70.Jin J-L, Guo Y-L, Li J-J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
